$FDMT insider trading
Over the last 12 months, 4D Molecular Therapeutics insiders reported no purchases and 18 sales totaling $3.8M across SEC Form 4 filings. 89% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3.8M 18 events
- Events · 12m
- 18 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 89% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | Bizily ScottChief Legal Officer · O | ▼ Sale | 584 | $14 | $8K | -6.3% | plan |
| Aug 19, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 69,076 | $15.75 | $1.1M | -7.7% | plan · 2 tranches |
| Aug 17, 2026 | Bizily ScottChief Legal Officer · O | ▼ Sale | 3,270 | $12.1 | $40K | -27.5% | plan · 2 tranches |
| Aug 4, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 26,842 | $10.23 | $275K | -3.1% | plan |
| Aug 3, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 12,415 | $10.05 | $125K | -1.4% | plan |
| Jul 10, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 58,333 | $12.64 | $737K | -6.2% | plan · 3 tranches |
| Jun 30, 2026 | Bizily ScottChief Legal Officer · O | ▼ Sale | 6,566 | $14 | $92K | -43.2% | plan |
| Jun 23, 2026 | Bizily ScottChief Legal Officer · O | ▼ Sale | 9,810 | $12 | $118K | -53.2% | plan |
| Jun 22, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 114,746 | $10.47 | $1.2M | -10.9% | plan |
| Jun 1, 2026 | Kirn DavidSee Remarks · O·D | ▼ Sale | 1,922 | $10.02 | $19K | -0.2% | plan |
| Mar 20, 2026 | Gupta AshooVP, Finance and Controller · O | ▼ Sale | 390 | $8.61 | $3K | -0.8% | 2 tranches |
| Dec 20, 2025 | Gupta AshooVP, Finance and Controller · O | ▼ Sale | 389 | $8.68 | $3K | -0.8% | 2 tranches |
| Dec 16, 2025 | Bizily ScottChief Legal Officer · O | ▼ Sale | 1,635 | $10.9 | $18K | -31.3% | plan |
| Nov 17, 2025 | Bizily ScottChief Legal Officer · O | ▼ Sale | 1,635 | $10.59 | $17K | -31.3% | plan |
| Oct 24, 2025 | Bizily ScottChief Legal Officer · O | ▼ Sale | 2,678 | $12 | $32K | -42.7% | plan |
| Oct 16, 2025 | Bizily ScottChief Legal Officer · O | ▼ Sale | 1,635 | $10.17 | $17K | -24% | plan |
| Oct 9, 2025 | Bizily ScottChief Legal Officer · O | ▼ Sale | 2,408 | $10 | $24K | -31.7% | plan |
| Sep 23, 2025 | Bizily ScottChief Legal Officer · O | ▼ Sale | 2,407 | $8 | $19K | -24.1% | plan |
Every $FDMT filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? 4D Molecular Therapeutics filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $FDMT feed.